ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.

Autor: Wrangle JM; Department of Medicine, Division of Hematology and Oncology, and Department of Surgery Medical University of South Carolina, Charleston, SC, USA., Velcheti V; Cleveland Clinic, Cleveland, OH, USA., Patel MR; Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN, USA., Garrett-Mayer E; Department of Medicine, Division of Hematology and Oncology, and Department of Surgery Medical University of South Carolina, Charleston, SC, USA., Hill EG; Department of Medicine, Division of Hematology and Oncology, and Department of Surgery Medical University of South Carolina, Charleston, SC, USA., Ravenel JG; Department of Medicine, Division of Hematology and Oncology, and Department of Surgery Medical University of South Carolina, Charleston, SC, USA., Miller JS; Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN, USA., Farhad M; Earle A Chiles Research Institute, Portland, OR, USA., Anderton K; Department of Medicine, Division of Hematology and Oncology, and Department of Surgery Medical University of South Carolina, Charleston, SC, USA., Lindsey K; Department of Medicine, Division of Hematology and Oncology, and Department of Surgery Medical University of South Carolina, Charleston, SC, USA., Taffaro-Neskey M; Department of Medicine, Division of Hematology and Oncology, and Department of Surgery Medical University of South Carolina, Charleston, SC, USA., Sherman C; Department of Medicine, Division of Hematology and Oncology, and Department of Surgery Medical University of South Carolina, Charleston, SC, USA., Suriano S; Department of Medicine, Division of Hematology and Oncology, and Department of Surgery Medical University of South Carolina, Charleston, SC, USA., Swiderska-Syn M; Department of Medicine, Division of Hematology and Oncology, and Department of Surgery Medical University of South Carolina, Charleston, SC, USA., Sion A; Department of Medicine, Division of Hematology and Oncology, and Department of Surgery Medical University of South Carolina, Charleston, SC, USA., Harris J; Department of Medicine, Division of Hematology and Oncology, and Department of Surgery Medical University of South Carolina, Charleston, SC, USA., Edwards AR; Department of Medicine, Division of Hematology and Oncology, and Department of Surgery Medical University of South Carolina, Charleston, SC, USA., Rytlewski JA; Adaptive Biotechnologies, Seattle, WA, USA., Sanders CM; Adaptive Biotechnologies, Seattle, WA, USA., Yusko EC; Adaptive Biotechnologies, Seattle, WA, USA., Robinson MD; Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland., Krieg C; Department of Medicine, Division of Hematology and Oncology, and Department of Surgery Medical University of South Carolina, Charleston, SC, USA., Redmond WL; Earle A Chiles Research Institute, Portland, OR, USA., Egan JO; Altor BioScience, Miramar, FL, USA., Rhode PR; Altor BioScience, Miramar, FL, USA., Jeng EK; Altor BioScience, Miramar, FL, USA., Rock AD; Altor BioScience, Miramar, FL, USA., Wong HC; Altor BioScience, Miramar, FL, USA., Rubinstein MP; Department of Medicine, Division of Hematology and Oncology, and Department of Surgery Medical University of South Carolina, Charleston, SC, USA. Electronic address: markrubinstein@musc.edu.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2018 May; Vol. 19 (5), pp. 694-704. Date of Electronic Publication: 2018 Apr 05.

Phase II trial of combined modality therapy with myeloid growth factor support in patients with locally advanced non-small cell lung cancer.

Autor: Lilenbaum R; Mount Sinai Cancer Center-Mount Sinai Clinical Community Oncology Program, Miami Beach, Florida 33140, USA. rlilenba@msmc.com, Samuels M, Taffaro-Neskey M, Cusnir M, Pizzolato J, Blaustein A

Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2010 Jun; Vol. 5 (6), pp. 837-40.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.

Autor: Saetersmoen, Michelle L.¹, Hammer, Quirin², Valamehr, Bahram³, Kaufman, Dan S.⁴, Malmberg, Karl-Johan^1,2,5 k.j.malmberg@medisin.uio.no

Publikováno v: Seminars in Immunopathology. Jan2019, Vol. 41 Issue 1, p59-68. 10p.

Lung Adenocarcinoma: Lessons in Translation from Bench to Bedside.

Autor: Sangodkar, Jaya¹, Katz, Suzanna¹, Melville, Heather¹, Narla, Goutham² goutham.narla@mssm.edu

Publikováno v: Mount Sinai Journal of Medicine. Nov/Dec2010, Vol. 77 Issue 6, p597-605. 9p. 2 Diagrams, 1 Chart.